MRT-6160

Small molecule

Also known as DDY391

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Featured evidence outside this drug's tracked markets:NCT06597799 · Healthy Volunteers · Phase 1 · completed · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (3)
Sjögren's Disease
Other / comorbidity
NCT07923773 · Novartis Pharmaceuticals
2027-02-10 – 2030-01-11 · Moderate to Severe Psoriatic Arthritis
What this study did
NCT07801495 · Novartis Pharmaceuticals
2026-10-19 – 2029-01-12 · Moderate to Severe Psoriatic Arthritis
What this study did
Phase 1 (1)
Other / comorbidity
NCT06597799 · Monte Rosa Therapeutics, Inc
2024-08-07 – 2025-04-10 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Sjögren's Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
MRT-6160: this drugPhase 2Small moleculeVAV1not yet gradedNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILPartial signal
NCT05673993: Primary endpoint, ESSDAI change at week 24 vs placebo: met; the release gives no figures (RemeGen, 2025-08-13).
VAY736Phase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow MRT-6160 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 2Moderate to Severe Psoriatic ArthritisRecruiting
Est. primary completion 2028-12-13 · NCT07801495 · CT.gov ↗
What to watch
2029 (2)
February 2029 (1)
Phase 2Sjögren's DiseaseRecruiting
Est. primary completion 2029-02-19 · NCT07737743 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Moderate to Severe Psoriatic ArthritisNot yet recruiting
Est. primary completion 2029-12-12 · NCT07923773 · CT.gov ↗
What to watch

See the full readout calendar ↗